Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023. | March 29, 2023
– Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and. | March 29, 2023
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934.
“We have now seen consistently across the program the potential to quite meaningfully reduce Phe levels in patients with PKU," lead investigator Dr. Jerry Vockley says in a statement.
Relief Therapeutics Holding SA / Key word(s): Study results17-March-2023 / 22:45 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLI.